The Booming Menopause Market: Are the Products Worth It?
What: Courtney Rubin does a deep dive from Women’s Health on which menopause products work, and which don’t. The main advice? If it sounds too good to be true, it probably is.
Key Line: “Most of these menopause products are not actually harmful, but they’re potentially a waste of time and money… As for pricey menopause retreats? Dr. Faubion calls them ‘ridiculous.’”
Once academic, now viral—this disinfectant may be the most powerful skin-safe cleanser yet.
Meghan Markle discusses rare and life-threatening postpartum condition on new podcast.
The 19th highlights how removing “DEI” efforts puts research on women’s health at risk.
Researchers call for standardized criteria to assess dangerous placenta conditions.
Mouse study reveals female hormones help trigger opioid production in spinal cord immune cells.
Cosmo breaks down Botox alternatives—and why your injector matters most.
ADF targets birth control and IUD coverage in campaign to cut ties with ACOG.
New GLP-1 pill for diabetes patients shows 7%+ weight loss, boosting Eli Lilly stock.
Young women now outpace young men in binge drinking, a reversal from previous years.
Breast pump startup Willow takes over UK-based Elvie’s assets, signaling tough market conditions for women’s health companies.
Federal research grants for women’s health are drying up under new Musk budget.
Hormone therapy may lower a genetic heart risk factor, new WHI data suggests.
The Trump administration has frozen federal family-planning grants, affecting groups like Planned Parenthood.
Marty Makary faces controversies as the new FDA commissioner.
New report calls women’s health a $360B ‘ghost market’ full of unmet needs across menopause, sexual health, aging, and more.
Researchers call for standardized criteria to assess dangerous placenta conditions.
Young women now outpace young men in binge drinking, a reversal from previous years.
A case at the Supreme Court could hit the entire Medicaid program by making key parts of the law unenforceable.
Interleukin-6 shows early promise in detecting life-threatening sepsis.
The New York Times dives into the ethics and limitations of using polygenic screening in IVF, highlighting the probabilistic nature of the predictions.